Sponsor or institution
Clinical trials and research at Innovent Biologics (Suzhou) Co. Ltd.
As of November 12, 2026, Find a Trial lists 31 clinical trials run by Innovent Biologics (Suzhou) Co. Ltd. that are recruiting, at sites in 4 countries (most in China (29), Australia (4), United States (2)). By phase: Phase 1 (12), Phase 3 (8), Phase 2 (6), Phase 1/2 (3). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 31Clinical trials
- 4Countries
Newest trials
All recruiting trials (31)
-
IBI3016 in Japanese adults with hypertension
A phase 1 study tests a single subcutaneous dose of IBI3016 in Japanese adults with mild to moderate high blood pressure to see if it is safe and how the body handles the drug.
-
IBI3046 in Overweight or Obesity
This study tests how safe and tolerable IBI3046 is in adults with overweight or obesity in China.
-
IBI3042: a first-in-human dose-finding study in adults with overweight or obesity
This is a Phase 1 trial testing IBI3042 in healthy adults and adults with overweight or obesity to see if it is safe and tolerable and to get a sense of how it works in the body, with some groups comparing to a placebo and, in Part B, to orforglipron.
-
See if IBI3027 works as well as Dupilumab for moderate to severe atopic dermatitis
This study tests whether IBI3027 can help people with moderate to severe atopic dermatitis as effectively as Dupilumab injections.
-
IBI363 with Bevacizumab for Advanced Colorectal Cancer
This phase 3 trial tests whether giving IBI363 with bevacizumab helps patients with advanced colorectal cancer who have not benefited from standard therapies.
-
A new treatment approach for relapsed or refractory multiple myeloma in adults
This study tests if IBI3003 works better than the investigator's choice treatment for adults whose multiple myeloma has returned or persisted after prior therapy.
-
IBI3031 in Thyroid Eye Disease (TED)
A first-in-human test in adults with moderate-to-severe TED to see if IBI3031 is safe and tolerable when given by shot under the skin or into a vein.
-
IBI3035 vs insulin injection bioequivalence in healthy adults
This small Phase 1 study in healthy Chinese men tests whether a single dose of IBI3035 behaves similarly to insulin (icodec) by checking blood levels and effects on glucose.
-
IBI115 in Advanced Small Cell Lung Cancer (SCLC) explores safety and early activity
This study tests IBI115 alone and with other therapies in adults with advanced SCLC to see if it is safe and shows signs of activity.
-
Safety and body handling of IBI3013 after single and multiple doses in healthy adults and men with active non-segmental vitiligo or severe alopecia areata
This trial tests whether IBI3013 is safe and how the body processes it in healthy adults and in men with active non-segmental vitiligo or severe alopecia areata.
-
IBI343 with sintilimab and SOX before and during surgery for resectable locally advanced gastric or GEJ cancer
A phase II trial tests whether adding IBI343 to sintilimab plus a SOX chemotherapy regimen around surgery helps people with CLDN18.2-positive, locally advanced gastric or GEJ cancer who are candidates for curative D2 surgery.
-
IBI343 in combination with chemotherapy for CLDN18.2-positive gastric cancer and pancreatic cancer
This study tests whether adding IBI343 to standard chemotherapy helps people with CLDN18.2-positive advanced gastric/gastroesophageal junction cancer or pancreatic ductal cancer.
-
See if IBI362 lowers blood pressure in adults who are overweight or obese
This study tests whether the drug IBI362 can help adults with high blood pressure who are overweight or obese, compared to placebo.
-
IBI3002 treatment for moderate to severe atopic dermatitis
This Phase 2 study will test whether the injectable drug IBI3002 helps adults with moderate to severe atopic dermatitis compared with dupilumab and placebo.
-
Teprotumumab N01 vs IV steroids for active thyroid eye disease
This trial tests whether teprotumumab N01 can help people with active thyroid eye disease better than intravenous steroids.
-
IBI362 for weight loss in Chinese adolescents with obesity or overweight
This research will see if different doses of IBI362 help Chinese adolescents aged 12–17 with obesity or overweight and weight-related health problems lose weight after diet and exercise did not produce at least a 5 kg reduction.
-
IBI363 or pembrolizumab plus chemotherapy before surgery for resectable stage IB–III non-squamous non-small cell lung cancer
This trial will see if giving IBI363 with chemotherapy or pembrolizumab with chemotherapy before surgery helps adults with resectable stage IB–III non-squamous non-small cell lung cancer and is safe.
-
Testing IBI311 for inactive thyroid eye disease.
This trial will test whether IBI311 improves eye signs and symptoms and is safe for people with inactive thyroid eye disease.
-
IBI343 versus placebo for CLDN18.2-positive advanced pancreatic cancer after at least two prior therapies
This trial tests whether IBI343 plus best supportive care can help people with CLDN18.2-positive locally advanced or metastatic pancreatic cancer who have had at least two prior treatments live longer than placebo plus best supportive care.
-
Taletrectinib for advanced ROS1-positive non-small cell lung cancer with brain metastases (real-world use)
This will try taletrectinib in adults with ROS1-positive non-small cell lung cancer that has spread to the brain to see how well it works and whether it is safe in routine care.
-
Treatment with IBI3014 for advanced solid tumors
This study is testing a new drug called IBI3014 to see if it can help people with advanced solid tumors that can't be surgically removed.
-
IBI362 for Chinese adults with obstructive sleep apnea and BMI ≥28
This trial will see if once-weekly IBI362 injections help Chinese adults with moderate-to-severe obstructive sleep apnea who have a BMI of 28 or higher.
-
Evaluating IBI3009 for advanced small cell lung cancer
This study is testing a new treatment called IBI3009 to see if it's safe and how much can be given to people with advanced small cell lung cancer that can't be removed by surgery.
-
Evaluating IBI363 for patients with advanced cancers
This study is testing a new treatment called IBI363 combined with chemotherapy to see if it helps people with advanced cancers who haven't responded to standard treatments.
-
Evaluating IBI3005 for advanced solid tumors
This study is testing a new drug called IBI3005 to see if it is safe and how much of it can be given to people with advanced solid tumors that haven't responded to previous treatments.
-
Evaluating IBI363 for advanced solid tumors
This study is testing a new treatment called IBI363 to see if it can help adults with advanced solid tumors like melanoma and lung cancer who have run out of other options.
-
Testing IBI3003 for patients with relapsed or refractory multiple myeloma
This study is testing a new treatment called IBI3003 to see if it can help people with relapsed or refractory multiple myeloma feel better and improve their health.
-
Evaluating IBI363 for advanced melanoma treatment
This study is testing a new treatment called IBI363 to see if it can help people with advanced melanoma who haven't had success with other therapies.
-
Testing IBI354 in patients with advanced solid tumors
This study is testing a new drug called IBI354 to see if it is safe and effective for people with advanced solid tumors that can't be removed by surgery.
-
Combining IBI351 with chemotherapy for advanced lung cancer with KRAS G12C mutation
This study is testing if a new drug called IBI351 can work better with chemotherapy for people with advanced lung cancer that has a specific KRAS G12C mutation.
-
Testing IBI343 in patients with advanced solid tumors
This study is testing a new drug called IBI343 to see if it is safe and effective for people with advanced solid tumors that can't be removed by surgery.
Quick answers
How many clinical trials run by Innovent Biologics (Suzhou) Co. Ltd. are recruiting right now?
31, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 4 countries. The most sites are in China (29 trials), Australia (4 trials), United States (2 trials), Japan (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 12, Phase 3: 8, Phase 2: 6, Phase 1/2: 3. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.